Enliven Therapeutics earnings update and what it means for the stock

Enliven Therapeutics (ELVN) recently reported second quarter and six month results to 30 June 2026. The company posted a quarterly net loss of US$32.49 million and a six month net loss of US$56.11 million.

Basic loss per share from continuing operations held at US$0.49 for the quarter compared with the same period last year. Over the six month period, basic loss per share from continuing operations was US$0.87 compared with US$1.05 a year earlier.

Against that earnings backdrop, Enliven Therapeutics’ share price has moved sharply higher, with a 30 day share price return of 12.91%, a 90 day gain of 43.50% and a very large year to date share price return of 286.55%. The 1 year total shareholder return of 204.00% and 3 year total shareholder return of 252.11% suggest strong momentum has been building over time.

If Enliven’s recent move has you thinking about where growth could come from next, it can be useful to scan other healthcare related AI opportunities using our 42 healthcare AI stocks

After such a strong move in Enliven Therapeutics, the share price now sits below the average analyst target by a clear margin. Does that gap still point to upside, or has fair value already been reached?

Preferred Price to Book multiple of 4.9x for Enliven Therapeutics: Is it justified?

On the latest figures, Enliven Therapeutics trades on a P/B of 4.9x, which analysts describe as good value versus a peer average of 5.7x, yet expensive relative to the broader US pharmaceuticals industry at 2.5x. That leaves the stock sitting between nearer term peer expectations and a wider sector reference point.

The P/B ratio compares the company’s market value to its book value, which is the net asset value on the balance sheet. For a clinical stage biopharma company like Enliven Therapeutics with no current revenue and ongoing losses, investors often lean on P/B because earnings based multiples such as P/E are not meaningful. A higher P/B can reflect expectations for future value creation from the pipeline rather than current profitability.

Against direct peers, the 4.9x P/B suggests the market is not assigning an unusually high premium to Enliven’s assets and oncology programs. However, compared with the wider US pharmaceuticals industry at 2.5x, the valuation looks much richer. That gap implies investors are willing to pay a higher price for each dollar of Enliven’s equity than for the average company in the industry.

The result is a mixed picture. Enliven Therapeutics appears attractively valued relative to its immediate peer group but expensive versus the broader sector on a P/B basis. Result: Price-to-book of 4.9x (ABOUT RIGHT)

However, recent share price gains, ongoing losses of US$105.93 million, and reliance on successful trial outcomes leave Enliven Therapeutics exposed if sentiment or clinical data shift.

Next Steps

With Enliven Therapeutics showing both risks and rewards in the current data, it makes sense to review the detail and decide quickly for yourself. To weigh both sides of the story in one place, start with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Enliven Therapeutics?

If Enliven Therapeutics has caught your attention, do not stop there. Widen your watchlist now and give yourself more options before the next move.

• Chase potential value by checking out companies that currently appear overlooked in our 50 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses featured in the 79 resilient stocks with low risk scores.
• Get ahead of the crowd with the screener containing 20 high quality undiscovered gems before others start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.